Fengxia Shi

1.4k total citations · 1 hit paper
16 papers, 1.0k citations indexed

About

Fengxia Shi is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Fengxia Shi has authored 16 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 5 papers in Immunology. Recurrent topics in Fengxia Shi's work include CAR-T cell therapy research (6 papers), Lymphoma Diagnosis and Treatment (4 papers) and Immune Cell Function and Interaction (4 papers). Fengxia Shi is often cited by papers focused on CAR-T cell therapy research (6 papers), Lymphoma Diagnosis and Treatment (4 papers) and Immune Cell Function and Interaction (4 papers). Fengxia Shi collaborates with scholars based in China, United States and Russia. Fengxia Shi's co-authors include Chaochao Tan, Ying Huang, Yong Chen, Xiaosong Li, Kui Tan, Xixin Jiang, Weidong Han, Yao Wang, Kaichao Feng and Hanren Dai and has published in prestigious journals such as Clinical Cancer Research, Signal Transduction and Targeted Therapy and Journal of Hematology & Oncology.

In The Last Decade

Fengxia Shi

16 papers receiving 981 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early

2020 392 citations Chaochao Tan, Ying Huang et al. Journal of Medical Virology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fengxia Shi China	11	517	379	219	191	153	16	1.0k
Robert Q. Le United States	8	397 0.8×	216 0.6×	163 0.7×	109 0.6×	162 1.1×	16	755
Alexandre V. Hirayama United States	14	1.1k 2.0×	415 1.1×	267 1.2×	316 1.7×	277 1.8×	61	1.7k
Paul‐Gerhardt Schlegel Germany	13	212 0.4×	101 0.3×	71 0.3×	152 0.8×	114 0.7×	36	771
Arne Sattler Germany	18	244 0.5×	295 0.8×	66 0.3×	115 0.6×	593 3.9×	32	1.2k
Changcheng Zheng China	14	168 0.3×	340 0.9×	146 0.7×	73 0.4×	69 0.5×	65	743
Anders Tveita Norway	19	403 0.8×	198 0.5×	87 0.4×	304 1.6×	627 4.1×	48	1.2k
Mehran Habibi United States	16	262 0.5×	98 0.3×	49 0.2×	164 0.9×	114 0.7×	63	872
Moshe E. Gatt Israel	19	433 0.8×	46 0.1×	73 0.3×	630 3.3×	174 1.1×	113	1.3k
Umar Zahid United States	10	187 0.4×	71 0.2×	41 0.2×	72 0.4×	61 0.4×	35	437
Hussain Alizadeh Hungary	18	238 0.5×	262 0.7×	43 0.2×	96 0.5×	78 0.5×	70	897

Countries citing papers authored by Fengxia Shi

Since Specialization

Citations

This map shows the geographic impact of Fengxia Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengxia Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengxia Shi more than expected).

Fields of papers citing papers by Fengxia Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengxia Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengxia Shi. The network helps show where Fengxia Shi may publish in the future.

Co-authorship network of co-authors of Fengxia Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Fengxia Shi. A scholar is included among the top collaborators of Fengxia Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengxia Shi. Fengxia Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Wang, Chunmeng, Yang Liu, Liang Dong, et al.. (2021). Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy. Clinical Cancer Research. 27(10). 2782–2791. 29 indexed citations

Wang, Chunmeng, Fengxia Shi, Yang Liu, et al.. (2021). Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy. Journal of Hematology & Oncology. 14(1). 1 indexed citations

Zhang, Juan, Junmin Zhang, Fengxia Shi, Weidong Tian, & Xiuzhen Liu. (2021). Therapeutic effect of a combination of montelukast and vitamins A and D drops in children with bronchial asthma, and its influence on quality of life. Tropical Journal of Pharmaceutical Research. 20(9). 2005–2011. 2 indexed citations

Shi, Fengxia, et al.. (2021). [Analysis of clinicopathological features of intrahepatic bile duct stones and its related occult cholangiocarcinoma].. PubMed. 50(4). 388–390. 1 indexed citations

Liu, Yang, Chunmeng Wang, Xiang Li, et al.. (2021). Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. Journal for ImmunoTherapy of Cancer. 9(4). e002347–e002347. 48 indexed citations

Shi, Fengxia, et al.. (2020). 2019 Novel Coronavirus (COVID-19) Pneumonia with Hemoptysis as the Initial Symptom: CT and Clinical Features. Korean Journal of Radiology. 21(5). 537–537. 46 indexed citations

Tan, Chaochao, Ying Huang, Fengxia Shi, et al.. (2020). C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early. Journal of Medical Virology. 92(7). 856–862. 392 indexed citations breakdown →

Liu, Yang, Yelei Guo, Zhiqiang Wu, et al.. (2020). Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial. Cytotherapy. 22(10). 573–580. 125 indexed citations

Tan, Chaochao, Li Yang, Fengxia Shi, et al.. (2019). Early Systemic Inflammatory Response Syndrome Duration Predicts Infected Pancreatic Necrosis. Journal of Gastrointestinal Surgery. 24(3). 590–597. 16 indexed citations

10.

Dai, Hanren, Chuan Tong, Yelei Guo, et al.. (2018). Restoration of CD3+CD56+ cell level improves skin lesions in severe psoriasis: A pilot clinical study of adoptive immunotherapy for patients with psoriasis using autologous cytokine-induced killer cells. Cytotherapy. 20(9). 1155–1163. 5 indexed citations

11.

Huang, Ying, Jie Xiao, Tao Cai, et al.. (2018). Immature granulocytes: A novel biomarker of acute respiratory distress syndrome in patients with acute pancreatitis. Journal of Critical Care. 50. 303–308. 29 indexed citations

12.

Zhang, Wenying, Hanren Dai, Yao Wang, et al.. (2016). An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Science China Life Sciences. 59(4). 379–385. 14 indexed citations

13.

Zhang, Wenying, Yao Wang, Yelei Guo, et al.. (2016). Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduction and Targeted Therapy. 1(1). 16002–16002. 104 indexed citations

14.

Dai, Hanren, Wenying Zhang, Xiaolei Li, et al.. (2015). Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. OncoImmunology. 4(11). e1027469–e1027469. 134 indexed citations

15.

Xia, Lei, Yan Zhang, Yao Wang, et al.. (2014). Analysis of adverse events following the treatment of autologous cytokine-induced killer cells for adoptive immunotherapy in malignant tumour sufferers. Expert Opinion on Biological Therapy. 15(4). 481–493. 9 indexed citations

16.

Fan, Hui, Xue-Chun Lu, Xiaohui Wang, et al.. (2014). Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report. Journal of Immunology Research. 2014. 1–14. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact